Stocks TelegraphStocks Telegraph
Stock Ideas

IVVD Company Profile and Key Details

NASDAQ : IVVD

Invivyd

$1.59
-0.12-7.02%
At Close 4:00 PM
$1.65
+0.06+3.82%
After-Market 08:30 PM
67.76
ESG ScoreESG Rating

Price Chart

Stock Price Today

Invivyd, Inc. (IVVD) stock declined over -7.02%, trading at $1.59 on NASDAQ, down from the previous close of $1.71. The stock opened at $1.77, fluctuating between $1.58 and $1.80 in the recent session.

Stock Snapshot

1.71
Prev. Close
211.04M
Market Cap
1.58
Day Low
-3.79
P/E Ratio
-0.42
EPS (TTM)
-1.58
Cash Flow per Share
1.77
Open
132.73M
Number of Shares
1.8
Day High
50.57%
Free Float in %
1.62
Book Value
5.55M
Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing DateAccepted Date

Annual Report (10-k)

Filing DateAccepted Date

Stock Price History Chart

DateOpenHighLowCloseVolume
Feb 06, 20261.761.801.581.595.56M
Feb 05, 20261.791.881.671.713.32M
Feb 04, 20261.921.961.771.843.09M
Feb 03, 20261.851.921.771.883.85M
Feb 02, 20261.761.901.721.743.9M
Jan 30, 20261.851.881.721.743.29M
Jan 29, 20261.941.961.831.852.29M
Jan 28, 20262.052.061.911.922.8M
Jan 27, 20262.042.081.982.032.82M
Jan 26, 20262.122.162.022.054.08M
Jan 23, 20262.202.212.092.113.02M
Jan 22, 20262.202.302.202.214.11M
Jan 21, 20262.252.292.152.212.75M
Jan 20, 20262.362.452.242.246.24M
Jan 16, 20262.412.522.402.451.8M
Jan 15, 20262.602.642.442.441.84M
Jan 14, 20262.332.612.322.604.53M
Jan 13, 20262.452.542.202.344.9M
Jan 12, 20262.562.562.332.454.33M
Jan 09, 20262.532.782.522.523.32M

Contact Details

Waltham, MA 02451

United States

https://adagiotx.com781 819 0080

About Company

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

Company Information

Employees99
Beta0.62
Sales or Revenue$0.00
5Y Sales Change%0%
Fiscal Year EndsDecember
SectorHealthcare
IndustryBiotechnology

Company Overview

Invivyd, Inc. (NASDAQ:IVVD) closed at $1.59 USD, losing -$0.12 (-7.02%) from the previous close of $1.71. The stock is currently mid-range between its 52-week high and low $0.46 and $3.07. With a market capitalization of about $211.04 million, Invivyd, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.60). Key stats such as the average daily volume over the past year has been around 6.74 million shares, in line with its 52-week average. Headquartered in Waltham, MA, Invivyd, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO William E. Duke Jr., the company employs approximately 99 people and listed since August 06, 2021. Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 -24.14%, SMA50 -30.77%, SMA200 13.51%). The stock’s 14-day RSI is 29.35 (weak momentum), while the ATR of 0.18 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -48.21% below its high and over 245.65% above its low. Average 10-day trading volume of 3.44 million shares is below the 3-month average of 6.58 million, indicating normal recent market interest.

Dividend & Fair Value

Invivyd, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $3.19. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Invivyd, Inc. generated EPS of -$0.47 over the past year. Five-year average earnings growth is -24.99%. Wall Street analysts project EPS growth of 48.75% annually over the next five years. The latest quarter delivered EPS of -$0.06. The next quarter is forecast at -$0.08. Next year's EPS is expected at $49.19. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 16 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $1.00. The high target offers 528.93% upside. The low target suggests -37.11% downside. The mean target is $7.35. This offers 362.26% upside. Invivyd, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 06, 2025, missed forecasts by 23.06%. The prior quarter beat by 200.0%. Over the last six quarters, Apple has recorded several small beats. These include 8.11% in August 14, 2024.

Shareholding & Insider Activity

Invivyd, Inc. has 120.14 million shares outstanding. The public float is 51.82 million shares, elevated short interest at 4.69% of float. This equals 3.33 million shares. The short ratio is 4.79 days. Institutional investors hold 75.18% of the float. Insiders own 19.2%. Adimab, LLC holds 21.69 million shares, MCGUIRE TERRANCE has 3.07 million shares and Andersen Jill has 84.45 thousand shares. Over the past six months, insider transactions show net selling. They sold 277.65 thousand shares across 10 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Invivyd has not generated any revenue. Returns are negative, with ROA at -86.68% and ROE at -111.93%.
On valuation metrics, Invivyd trades at a P/E of -4.61, P/S of 4.30 and P/B of 2.96. The current ratio is 2.47 and quick ratio is 2.47. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -1911.91 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.03, supported by a cash flow-to-debt ratio of -29.99.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Invivyd posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $2.03M (margin 0.00%). Operating income was - $207.78M (margin 0.0%). Net income was- $198.64M (EPS - $1.81).
The company ended the quarter with $200.64M in cash and short-term investments, a total debt of $2.17M, and net debt of - $198.48M. Total assets were $229.18M, with equity of $177.47M. Financials further reflected weakness, with operating cash flow of - $173.16M, free cash flow of - $173.78M, and capital expenditures of - $615.00K.

Frequently Asked Questions

What is the current Invivyd, Inc. (IVVD) stock price?
Invivyd, Inc. (NASDAQ: IVVD) stock price is $1.59 in the last trading session. During the trading session, IVVD stock reached the peak price of $1.80 while $1.58 was the lowest point it dropped to. The percentage change in IVVD stock occurred in the recent session was -7.02% while the dollar amount for the price change in IVVD stock was - $0.12.
IVVD's industry and sector of operation?
The NASDAQ listed IVVD is part of Biotechnology industry that operates in the broader Healthcare sector. Invivyd, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of IVVD?
Ms. Laura Walker Ph.D.
Co-Founder & Chief Scientific Officer
Ms. Jill Andersen J.D.
Chief Legal Officer & Corporation Sec.
Mr. David Hering M.B.A.
Chief Executive Officer & Director
Ms. Kyra Rosow Faircloth M.S.
Vice President of Gov. Affairs, Advocacy & Corporation Communication
Ms. Stacy Price
Chief Technology & Manufacturing Officer
Dr. Elham Hershberger Pharm.D.
Chief Devel. Officer
Mr. Jeremy Gowler
Chief Operating Officer & Chief Commercial Officer
Kyra Rosow Faircloth
Vice President of Gov. Affairs, Advocacy & Corporation Communication
Dr. Rebecca Dabora Ph.D.
Chief Technology & Manufacturing Officer
Ms. Stacy Price M.S.
Chief Technology & Manufacturing Officer
Dr. Peter Schmidt M.D.
Chief Medical Officer
Dr. Peter C. Schmidt M.D., M.S., M.Sc.
Chief Medical Officer
Ms. Heidi Spurling M.S.
Vice President of Strategy & Operations and Chief of Staff to the Chief Executive Officer
Dr. Peter C. Schmidt M.D., M.Sc.
Chief Medical Officer
Ms. Kyra Rosow Faircloth
Vice President of Gov. Affairs, Advocacy & Corporation Communication
Ms. Julie Green M.B.A.
Senior Vice President of HR
Lukas Dillinger Ph.D.
Interim Head of Discovery & Pre-Clinical
Mr. Frederick W. Driscoll
Interim Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer
Ms. Heidi Spurling
Vice President of Strategy & Operations and Chief of Staff to the Chief Executive Officer
Dr. Robert D. Allen Ph.D.
Chief Scientific Officer
How IVVD did perform over past 52-week?
IVVD's closing price is 245.65% higher than its 52-week low of $0.46 where as its distance from 52-week high of $3.07 is -48.21%.
How many employees does IVVD have?
Number of IVVD employees currently stands at 99.
Link for IVVD official website?
Official Website of IVVD is: https://adagiotx.com
How do I contact IVVD?
IVVD could be contacted at phone 781 819 0080 and can also be accessed through its website. IVVD operates from 1601 Trapelo Road, Waltham, MA 02451, United States.
How many shares of IVVD are traded daily?
IVVD stock volume for the day was 5.55M shares. The average number of IVVD shares traded daily for last 3 months was 6.74M.
What is the market cap of IVVD currently?
The market value of IVVD currently stands at $211.04M with its latest stock price at $1.59 and 132.73M of its shares outstanding.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph